GPR119 is expressed in insulin-producing beta cells where it modulates insulin release, thus making it a very attractive therapeutic target for metabolic disorders. GPR119 is activated by oleoylethanolamide (OEA) and by a novel selective small-molecule (PSN632408) which, when administered to high-fat-fed rats, suppresses food intake and reduces body weight gain. Another small molecule full-agonist (AR231453) enhances glucose-dependent insulin release, and improves oral glucose tolerance in wild-type mice, but not in GPR119 knock-out mice.
Human GPR119 Receptor EZCells™ DA
For pricing information, detailed technical sheets, or to speak with one of our experts, please contact us at 1.877.CRIVER.1 (1.877.274.8371) or by using our online form.
Can't find what you are looking for? Contact us. We are always developing new cell lines and can work with you on custom projects.